SCHEMBL23219084

SCHEMBL23219084

CCOC(=O)Cc1ccccc1OCc1coc2c(CN3CCN(C)CC3)cc(Br)cc12

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.39
TBXAS1 P24557 1/20 0.39
ALDH1A1 P00352 6/20 0.39
THRB P10828 1/20 0.39
CCR5 P51681 2/20 0.38
GAA P10253 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
MAPT P10636 1/20 0.38
POLB P06746 3/20 0.38
KMT2A Q03164 2/20 0.37
MEN1 O00255 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
ALOX15 P16050 1/20 0.37
HTT P42858 1/20 0.37
HPGD P15428 2/20 0.36
HSD17B10 Q99714 2/20 0.36
MTNR1A P48039 1/20 0.36
LMNA P02545 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23218351 0.93 CCR5 (0.39) KDM4ETBXAS1ALDH1A1CCR5MAPT
SCHEMBL29852448 0.93 CCR5 (0.39) KDM4ETBXAS1ALDH1A1CCR5MAPT
SCHEMBL28736146 0.92 KDM4E (0.39) KDM4ETBXAS1ALDH1A1CCR5MAPT
SCHEMBL23218445 0.92 CCR5 (0.40) KDM4ETBXAS1ALDH1A1CCR5GAA
SCHEMBL23218227 0.89 CCR5 (0.37) KDM4ETBXAS1ALDH1A1CCR5GAA
SCHEMBL29852778 0.88 ALDH1A1 (0.40) KDM4EALDH1A1CCR5TDP1MAPT
SCHEMBL23218587 0.88 ALDH1A1 (0.40) KDM4EALDH1A1CCR5TDP1MAPT
SCHEMBL29852449 0.87 CCR5 (0.40) KDM4ETBXAS1ALDH1A1CCR5MAPT
SCHEMBL23229202 0.87 CCR5 (0.40) KDM4ETBXAS1ALDH1A1CCR5MAPT
SCHEMBL23218283 0.87 KDM4E (0.36) KDM4ETBXAS1ALDH1A1CCR5GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
EP-4041238-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 EP disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB KDM4E 4172/4885TBXAS1 963/4885ALDH1A1 2667/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB KDM4E 4491/4885TBXAS1 392/4885ALDH1A1 3142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.